# Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

> **NCT01520922** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 99 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Leukaemia, Lymphocytic, Chronic

## Interventions

- **BIOLOGICAL:** Ofatumumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT01520922
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-02
- **Final completion:** 2015-11
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520922, "Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01520922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*